Attenuating Ischemia Reperfusion Injury After Living Donor Renal Transplantation

Attenuating Ischemia Reperfusion Injury After Living Donor Renal Transplantation

Patients undergoing living donor renal transplant will be asked to participate to determine whether pre-operative dosing of immunosuppressive medication, and the donor organ receiving an additional dose of antibody induction therapy helps to alleviate potential damage to the transplanted organ post-transplant. A number of lab tests will be done post-transplant to determine how well the kidney is functioning.

Inclusion Criteria:

1. Must be able to provide written informed consent.
2. All recipients of a kidney from a living donor only, either a de novo transplant, or re-transplant
3. All patients evaluated and listed with the United Network for Organ Sharing (UNOS) who are eligible to receive a kidney transplant under GUH's standard protocol.
4. Patients between 18-80 years of age

Exclusion Criteria:

1. Recipients of multi-organ transplant
2. Patients with known allergies of hypersensitivities to any of the drugs used in this protocol
3. Recipients of kidneys from a deceased donor
4. Recipients who are co-infected with Hepatitis B, Hepatitis C or HIV
5. Women who are pregnant
6. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle or sexual orientation precludes intercourse with a male partner unless they agree to avoid pregnancy throughout the duration of the trial and for 3 months following the trial.